| Autor: |
Terpos, E. Repousis, P. Lalayanni, C. Hatjiharissi, E. Assimakopoulou, T. Vassilopoulos, G. Pouli, A. Spanoudakis, E. Michalis, E. Pangalis, G. Ntanasis‐stathopoulos, I. Poziopoulos, C. Kyrtsonis, M.-C. Pappa, V. Symeonidis, A. Georgopoulos, C. Zikos, P.M. Gavriatopoulou, M. Papadaki, H.A. Dadakaridou, M. Karvounis‐marolachakis, K. Katodritou, E. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low‐dose dexamethasone (POM/LoDex) therapy in relapsed/re-fractory multiple myeloma in routine care in Greece. Ninety‐nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 Feb-ruary 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third‐line treatment. During the treatment period (median: 8.3 months; range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow‐up period of 13.8 months (Kaplan–Meier estimate), the median progression‐free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow‐up (N = 75), POM‐related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM‐related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real‐world study, POM/LoDex displayed a long PFS with no new safety signals emerging. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
